Results 11 to 20 of about 50,528 (188)
Abstract Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 expresses in almost all blasts of T-cell lymphoma/leukemia and represents one of the most promising therapeutic targets for T-ALL/LBL by CD7 targeted chimeric
Huimin Meng+7 more
semanticscholar +4 more sources
We present a four-year-old girl with synchronous T-cell lymphoblastic lymphoma (T-LBL) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL).Development of two lymphoid malignancies arising from completely different cell lineages was confirmed by ...
Joanna Bulsa+5 more
doaj +3 more sources
Although deletions of cell cycle regulatory gene loci have long been reported in various malignancies, little is known regarding their relevance in pediatric T-cell lymphoblastic lymphoma (T-LBL) and T-cell lymphoblastic leukemia (TALL).
David Krieger+6 more
doaj +4 more sources
ABL oncogene amplification with p16INK4a gene deletion in precursor T‐cell acute lymphoblastic leukemia/lymphoma: Report of the first case [PDF]
AbstractGene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto‐oncogene and is the well‐known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute ...
Koo Hh+4 more
semanticscholar +4 more sources
Introduction: T-cell acute lymphoblastic leukemia (T-ALL) originating from early T-cell precursors (ETP-ALL) has distinct immunophenotype (CD1a-CD8-CD5-/weak and positive for myeloid or stem-cell markers [My-HSC+]) and is associated with poor outcome with 5-year (yr) survival <25%. Some T-ALL cases are transcriptionally similar to
Nicholas J. Short+19 more
semanticscholar +4 more sources
Abstract Background: The Early T-cell precursor (ETP) variant of acute lymphoblastic lymphoma/leukemia (ALL) is a recognized high risk variant, recognized by the absence of CD1a, with aberrant myeloid antigen expression (CD13, CD33, CD117, and CD34), and frequent absence of CD4 or CD8. Treatment intensification may improve
Deniz Peker+6 more
semanticscholar +4 more sources
Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. [PDF]
We compared the antigen expression profile of thymocytes in lymphocyte-rich thymoma with that of precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-cell ALL/LBL) cells using 4-colorflow cytometry.
Shiyong Li, J. Juco, K. Mann, J. Holden
semanticscholar +3 more sources
T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) arise from the transformation of precursor T-cells sharing common morphological and immunophenotypic features.
Giulia Veltri+18 more
doaj +2 more sources
Although relapse of lymphoma/leukemia is not uncommon, sequential development of a second lymphoma/leukemia of a different cell lineage is rare. We report the case of a 3-year-old girl who initially presented with precursor B-cell acute lymphoblastic ...
Jenny L. Smith+5 more
semanticscholar +3 more sources
Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. [PDF]
Session 4 of the 2005 Society of Hematopathology/European Association for Haematopathology Workshop focused on case presentations of precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (pre-T ALL/LBL) and acute biphenotypic leukemia. Pre-
Xin Han, C. Bueso-Ramos
semanticscholar +3 more sources